CPT 80306: Presumptive Drug Screen, Instrument-Read
Commercial payers pay $30 on average nationally for this procedure.
CPT code 80306 describes a presumptive drug screening performed by a laboratory analyst using instrument-assisted direct optical observation (commonly immunoassay) to screen one or more drug classes on a single date; service type: presumptive toxicology/drug screen (instrument-read immunoassay); typical site of service: clinical laboratory or outpatient laboratory collection site where instrument-based immunoassay testing is performed.
Customize your policy alerts
Sign up for cpt 80306 policy alerts
Get alerted when payer policies referencing 80306 are released or updated.
Monitor payer policy activity
National Reimbursement Benchmarks
Across national commercial payers, BUCA (average commercial) centers near $30.4 for CPT 80306, offering a useful midpoint for comparison. Blue Cross Blue Shield displays the highest mean at $42.5 and a wide interquartile spread ($44.10 p75 minus $37.80 p25 = $6.30), while Cigna’s mean of $16.4 and Aetna’s mean of $12.6 sit well below BUCA. UnitedHealth Group and Aetna have lower medians ($10.3 and $13.0 respectively) compared with Blue Cross Blue Shield and Cigna.
Dispersion varies meaningfully by payer: Blue Cross Blue Shield’s IQR equals $6.30, the widest among payers, indicating greater regional or contractual variability. UnitedHealth Group shows a tighter IQR of $9.00 (p75 $17.10 minus p25 $7.20 = $9.90) and Cigna’s IQR is $12.40 (p75 $21.40 minus p25 $9.00 = $12.40), while Aetna’s IQR is $6.00 (p75 $16.00 minus p25 $10.00 = $6.00), making Aetna one of the tighter distributions around its median.